1. Baines AT, Xu D, Der CJ. (2011) Inhibition of Ras for cancer treatment: the search continues. Future Med Chem, 3 (14): 1787-808. [PMID:22004085]
2. Bezniakow N, Gos M, Obersztyn E. (2014) The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes. Dev Period Med, 18 (3): 285-96. [PMID:25182392]
3. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. (2005) Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res, 65 (3): 999-1006. [PMID:15705901]
4. Bos JL. (1989) ras oncogenes in human cancer: a review. Cancer Res, 49 (17): 4682-9. [PMID:2547513]
5. Ebi H, Faber AC, Engelman JA, Yano S. (2014) Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers. Cancer Sci, 105 (5): 499-505. [PMID:24612015]
6. Goitre L, Trapani E, Trabalzini L, Retta SF. (2014) The Ras superfamily of small GTPases: the unlocked secrets. Methods Mol Biol, 1120: 1-18. [PMID:24470015]
7. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature, 503 (7477): 548-51. [PMID:24256730]
8. Rotblat B, Ehrlich M, Haklai R, Kloog Y. (2008) The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Meth Enzymol, 439: 467-89. [PMID:18374183]
9. Wennerberg K, Rossman KL, Der CJ. (2005) The Ras superfamily at a glance. J Cell Sci, 118 (Pt 5): 843-6. [PMID:15731001]